A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection

[1]  Kouji Matsushima,et al.  CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways , 2019, The Journal of experimental medicine.

[2]  K. Edwards,et al.  Gel Phase 1,2-Distearoyl-sn-glycero-3-phosphocholine-Based Liposomes Are Superior to Fluid Phase Liposomes at Augmenting Both Antigen Presentation on Major Histocompatibility Complex Class II and Costimulatory Molecule Display by Dendritic Cells in Vitro , 2019, ACS Infectious Diseases.

[3]  J. Stambas,et al.  CXCR6-Deficiency Improves the Control of Pulmonary Mycobacterium tuberculosis and Influenza Infection Independent of T-Lymphocyte Recruitment to the Lungs , 2019, Front. Immunol..

[4]  S. Akira,et al.  Intestinal CD103+CD11b+ cDC2 Conventional Dendritic Cells Are Required for Primary CD4+ T and B Cell Responses to Soluble Flagellin , 2018, Front. Immunol..

[5]  Maxim Shevtsov,et al.  Nanoparticle Vaccines Against Infectious Diseases , 2018, Front. Immunol..

[6]  Wei Zhang,et al.  Recent advances in understanding dendritic cell development, classification, and phenotype , 2018, F1000Research.

[7]  X. Saelens,et al.  Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections , 2018, Front. Immunol..

[8]  N. Lycke,et al.  ADP‐ribosylating enterotoxins as vaccine adjuvants , 2018, Current opinion in pharmacology.

[9]  B. Corthésy,et al.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection , 2018, Front. Immunol..

[10]  P. Burkhard,et al.  Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine. , 2017, Vaccine.

[11]  W. Fiers,et al.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection , 2017, Mucosal Immunology.

[12]  P. Boyaka.  Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems , 2017, The Journal of Immunology.

[13]  Daniel K. Bonner,et al.  Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses. , 2017, Biomaterials.

[14]  Xun Sun,et al.  Engineering intravaginal vaccines to overcome mucosal and epithelial barriers. , 2017, Biomaterials.

[15]  W. Fiers,et al.  M2-based influenza vaccines: recent advances and clinical potential , 2017, Expert review of vaccines.

[16]  V. Kett,et al.  Current prospects and future challenges for nasal vaccine delivery , 2017, Human vaccines & immunotherapeutics.

[17]  Y. Jang,et al.  The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants , 2017 .

[18]  F. Höök,et al.  Mucosal Vaccine Development Based on Liposome Technology , 2016, Journal of immunology research.

[19]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[20]  H. Oberoi,et al.  PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Xiaoqun Gong,et al.  Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo. , 2015, ACS nano.

[22]  M. Strioga,et al.  Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines , 2015, Vaccines.

[23]  W. Fiers,et al.  M2e-Based Universal Influenza A Vaccines , 2015, Vaccines.

[24]  Adeeb H. Rahman,et al.  Phenotype and function of nasal dendritic cells , 2015, Mucosal Immunology.

[25]  A. Molinari,et al.  Liposomes as nanomedical devices , 2015, International journal of nanomedicine.

[26]  V. Poon,et al.  An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus , 2015, Emerging Microbes & Infections.

[27]  Ting-Yu Shih,et al.  Brain-Penetrating Nanoparticles Improve Paclitaxel Efficacy in Malignant Glioma Following Local Administration , 2014, ACS nano.

[28]  R. Schwendener,et al.  Liposomes as vaccine delivery systems: a review of the recent advances , 2014, Therapeutic advances in vaccines.

[29]  H. Ploegh,et al.  Early BCR Events and Antigen Capture, Processing, and Loading on MHC Class II on B Cells , 2014, Front. Immunol..

[30]  I. Caminschi,et al.  New generation of dendritic cell vaccines , 2013, Human vaccines & immunotherapeutics.

[31]  Xi Zhan,et al.  Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration. , 2012, Molecular pharmaceutics.

[32]  M. Merad,et al.  Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. , 2012, The Journal of clinical investigation.

[33]  N. Lycke.  Recent progress in mucosal vaccine development: potential and limitations , 2012, Nature Reviews Immunology.

[34]  Leaf Huang,et al.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. , 2012, Vaccine.

[35]  Walter Fiers,et al.  A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. , 2011, Vaccine.

[36]  W. Fiers,et al.  M2e-based universal influenza A vaccine. , 2009, Vaccine.

[37]  W. Fiers,et al.  CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. , 2008, Vaccine.

[38]  H. Bobichon,et al.  Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction. , 2006, Biochimica et biophysica acta.

[39]  W. Fiers,et al.  Universal influenza A vaccine: optimization of M2-based constructs. , 2005, Virology.

[40]  J. Oxford,et al.  Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. , 2004, Vaccine.

[41]  K. Schön,et al.  The Cholera Toxin-Derived CTA1-DD Vaccine Adjuvant Administered Intranasally Does Not Cause Inflammation or Accumulate in the Nervous Tissues1 , 2004, The Journal of Immunology.

[42]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[43]  N. Lycke,et al.  Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. , 1999, Journal of immunology.

[44]  B. Löwenadler,et al.  A novel concept in mucosal adjuvanticity: The CTA1‐DD adjuvant is a B cell‐targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit , 1998, Immunology and cell biology.

[45]  B. Spangler.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin , 1992 .

[46]  B. Spangler,et al.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. , 1992, Microbiological reviews.

[47]  C. Janeway,et al.  A novel MHC class II epitope expressed in thymic medulla but not cortex , 1989, Nature.

[48]  P. Marrack,et al.  Antigen presentation by Ia+ B cell hybridomas to H-2-restricted T cell hybridomas. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[49]  W. Dowdle,et al.  Antigenic variation in current human type A influenza viruses: antigenic characteristics of the variants and their geographic distribution. , 1973, Bulletin of the World Health Organization.